770 related articles for article (PubMed ID: 23543652)
1. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
4. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
5. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
6. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
Novakovic V; Adel T; Peselow E; Lindenmayer JP
Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
[TBL] [Abstract][Full Text] [Related]
7. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.
Citrome L
Expert Rev Neurother; 2013 Jul; 13(7):767-83. PubMed ID: 23898849
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine pamoate for the treatment of schizophrenia.
Naber D
Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long acting injectable atypical antipsychotics: a review.
De Berardis D; Marini S; Carano A; Lang AP; Cavuto M; Piersanti M; Fornaro M; Perna G; Valchera A; Mazza M; Iasevoli F; Martinotti G; Di Giannantonio M
Curr Clin Pharmacol; 2013 Aug; 8(3):256-64. PubMed ID: 23343445
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS
JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of long-acting antipsychotic medications.
Spanarello S; La Ferla T
Curr Clin Pharmacol; 2014; 9(3):310-7. PubMed ID: 23343447
[TBL] [Abstract][Full Text] [Related]
14. Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.
Decuypere F; Sermon J; Geerts P; Denee TR; De Vos C; Malfait B; Lamotte M; Mulder CL
PLoS One; 2017; 12(6):e0179049. PubMed ID: 28614404
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
[TBL] [Abstract][Full Text] [Related]
16. Long-acting injectable antipsychotics in early psychosis: a literature review.
Emsley R; Chiliza B; Asmal L; Mashile M; Fusar-Poli P
Early Interv Psychiatry; 2013 Aug; 7(3):247-54. PubMed ID: 23342964
[TBL] [Abstract][Full Text] [Related]
17. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
18. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
Möller HJ
Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
[TBL] [Abstract][Full Text] [Related]
19. Second-generation long-acting injectable antipsychotic agents: an overview.
Drug Ther Bull; 2012 Sep; 50(9):102-5. PubMed ID: 22966099
[TBL] [Abstract][Full Text] [Related]
20. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
Faludi G
Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
